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Abstract
Background: Different management options exist for patients with brain metastases from non-small cell lung cancer
(NSCLC), patients whose treatment with whole brain radiotherapy (WBRT) has become more controversial over the last
decade. It is not trivial to find the optimal balance of over- versus undertreatment in these patients. Several recent trials,
including the randomized QUARTZ trial now influence the decision to recommend or withhold WBRT for patients with
unfavorable prognosis, and similarly, for favorable prognosis patients, the balance between radiosurgery alone or WBRT
has become a nuanced decision. Additionally, the availability of intracranially active targeted agent for some subsets of
these patients has added another layer of complexity to the decision-making.
Methods: A multinational consortium of expert radiation oncologists was established with the aim of compiling treatment
recommendations for challenging scenarios, in this case the choice between optimal supportive care (SC), WBRT and other
types of radiation therapy (RT). We distributed 17 cases to 7 radiation oncologists who were allowed to involve coworkers to
provide their treatment recommendations. The cases differed in extra- and intracranial disease extent, histology, age and
other prognostic factors. Expert recommendations were tabulated with the aim of providing guidance.
Results: Regarding willingness to include the 17 patients in the QUARTZ trial, the rates of trial inclusion were low (range 0/7
to 3/7). Experts not recommending trial inclusion provided their treatment recommendations. These suggestions differed
widely for most of the patients. It was not uncommon to see 3 or 4 different recommendations. In general, few (0–2)
recommended SC. Some kind of local treatment was suggested by the majority of experts for all 17 patients. Commonly,
stereotactic single-fraction radiosurgery (SRS) or stereotactic fractionated radiotherapy (SFRT) were recommended by many
experts, also for patients with 5–7 lesions. The highest proportion of recommendations towards WBRT in any patient was 3/
7. It was also quite common for patients with multiple metastases of varying size that experts suggested combinations of
resection, post-operative SRS/SFRT and SRS/SFRT to intact lesions. Despite recommending active treatment, experts were
often willing to include the patients in a hypothetical protocol investigating radiotherapy utilization in the last 30 days of life
(assessment of factors predicting early death).
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Conclusions:WBRT was infrequently recommended. Even in patients with adverse prognostic features that raised the
experts’ awareness of an increased risk for futile treatment near the end of life, SRS/SFRT were more often recommended
than optimal supportive care, unless a patient decided to forego active treatment.
Keywords: Brain metastases, Non-small cell lung cancer, Prognostic factors, Radiosurgery, Whole brain radiation therapy,
Introduction
The management options for patients with brain metas-
tases from non-small cell lung cancer (NSCLC) have
never been more diverse than in the present era [1–3].
While it has been recognized for decades that patients
with a solitary lesion might live disease-free for many
years after effective treatment, this scenario is uncom-
mon [4]. Most patients present with more than one
brain metastasis and have additional extracranial metas-
tases in the liver, adrenal glands and/or bones. If accom-
panied by reduced performance status and other adverse
prognostic features, patients with multiple metastases to
multiple organs have been shown repeatedly to have lim-
ited survival, e.g., after whole brain radiotherapy
(WBRT) [5–7]. However with advanced radiation treat-
ment modalities and evolving systemic treatment op-
tions [8–10] survival outcomes of individual patients
might be better or worse than anticipated from prognos-
tic models. Parallel to other developments, these models
have been refined and now take into account the differ-
ent histologic and molecular subsets of NSCLC [11–14].
This is of particular relevance, because even patients
with poor performance scores and multiple brain metas-
tases and extracranial disease, if harboring an actionable
mutation, often respond dramatically to targeted
therapies.
Among several current controversies, one relates to
the management of patients with adverse prognostic fea-
tures, where overly aggressive treatment in the final
weeks of life is not uncommon [15–17]. In order to shed
more light on the role of WBRT in patients not suitable
for neurosurgical resection and/or stereotactic radiosur-
gery (SRS), the prospective randomized QUARTZ trial
was performed [18]. Despite initial difficulties in patient
accrual [19], 538 patients were recruited from 69 UK
and three Australian centers between 2007 and 2014.
The protocol required uncertainty in the clinicians’ or
patients’ minds about the potential benefit of WBRT and
used a non-inferiority design. All patients were offered
optimal supportive care (SC) including dexamethasone,
which a significant majority received. In the WBRT arm
treatment consisted of 5 fractions of 4 Gy each. The pri-
mary outcome measure was quality-adjusted life-years
(QALYs). Median age was 66 years (range 38–85). The
authors concluded that there was no significant differ-
ence in QALYs between the two treatment arms (mean
46.4 QALY days for the WBRT arm vs 41.7 QALY days
for WBRT and SC, respectively). It is important to re-
member, however, that the tool used to measure QALY
had several questions which pertained to common side
effects of steroids, and since these were liberally used in
both arms, no QALY difference could realistically have
been expected. There was also no significant difference
observed in overall survival (hazard ratio 1.06, 95% CI
0.90–1.26), quality of life, or dexamethasone usage be-
tween the two groups.
The potential impact of these QUARTZ findings and on-
going controversy around their influence on current man-
agement, stimulated our multinational group to gather,
compare and contrast our management of brain metastases
in patients with NSCLC. This group has previously applied
this strategy to other areas of controversy [20, 21].
Methods
Representatives (radiation oncologists, some with focus
on neuro-oncology, others with focus on lung cancer,
many with experience in both fields) from seven aca-
demic institutions (hereafter referred to as “partici-
pants”) were provided with uniform clinical, diagnostic,
and therapeutic information, including critical slices of
imaging studies. Within their own institution, the partic-
ipants had permission to present the cases to their col-
laborators/tumor boards. All institutions had the
possibility to treat with WBRT, stereotactic single-frac-
tion radiosurgery (SRS) or stereotactic fractionated
radiotherapy (SFRT). Treatment recommendations were
then compiled using a standardized template requesting
answers to three different questions. Results from each
participant were collated and presented back to the
group of participants without disclosing the recommen-
dations by any identifying information.
Clinical information distributed to the participating
experts
Clinical baseline data and the critical parts of imaging
studies from 17 patients were sent to the seven participants
(Table 1). Imaging was provided as per the Additional file 1:
Figure S1. All patients had symptomatic brain metastases
rather than imaging or screen-detected lesions. Number
and size of brain metastases were based on
contrast-enhanced brain MRI scans. If these scans
were not stored, the corresponding CT scans were sent
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to the participating experts. The Karnofsky performance
status (KPS) was scored at the time of radiation oncology
consultation, following the initiation of steroids. Informa-
tion about PD-L1 status was not available. In cases where
the primary tumor was controlled, thoracic CT scans were
not sent out. A brief overview of the QUARTZ inclusion/
exclusion criteria was also attached to the distributed
material. For all patients, prognostic information
according to the disease-specific graded prognostic as-
sessment (DS-GPA), molecular DS-GPA, the
Barnholtz-Sloan and Zindler nomograms was also
provided [12, 14, 15].
All 17 patients had unfavorable prognostic features,
reflected in the low DS-GPA and molecular DS-GPA
scores (max. 1.5 points, median 0.5 and 1.0, respect-
ively). Five patients had a KPS of 70, the others 50–60.
Sixteen patients had extracranial metastases and only
one a targetable molecular alteration (EGFR mutation).
According to the Barnholtz-Sloan nomogram [14], the
median survival that could be expected for this sample
was 2.6 months.
Since these 17 cases were real cases, the actual man-
agement employed and the survival outcome was known
and released to the participants after they provided their
input. The actual management employed SC in 10 pa-
tients and WBRT (5 fractions of 4 Gy) in 7, respectively.
The WBRT group survived for a median of 1.3 months
from the first day of radiotherapy. The SC group
Table 1 Patient characteristics and (in the last column) answers to the question about inclusion in the randomized QUARTZ study
(number of participants who would have felt comfortable enrolling the patient)
Patient
nr.
Age in
years
NSCLC
type
Primary tumor
controlled
Other
metastases
KPS Largest lesion
size [cm]
Lesion
number (MRI)
Time int.
[mo]a
Mol DS-
GPA
DS-
GPA
OS
predb
QUARTZ
incl.
1 69 squamous
cell
yes hep 50 3.8 3 10 1.0 0.5 2.3 2
2 60 poorly diff. no lym, adr,
hep, ski
50 1.3 2 2 1.0 1.0 2.7 2
3 58 adeno
NSCLC
no hep, oss,
oth
60 4.5 3 0 1.0 1.0 3.1 2
4 69 poorly diff. no hep, oss 60 2.1 1 8 1.0 1.0 2.6 2
5 61 poorly diff. no hep, adr,
pul
60 3.3 7 10 0.5 0.0 2.6 2
6 64 squamous
cell
no pul, kidney 70 1.5 1 20 1.0 1.5 2,6 0
7 85 squamous
cell
no pul 60 1.8 1 18 0.5 1.0 < 2.0 2
8 66 adeno
NSCLC
no oss, adr,
lym
60 1.0 7 0 0.5 0.0 2.8 1
9 65 poorly diff. no pul, oth 50 2.0 2 5 1.0 0.5 2.4 2
10 77 adeno
NSCLC
yes none 50 2.3 6 12 1.0 1.0 3.8 1
11 62 adeno
NSCLC
yes adr 70 2.1 5 29 0.5 0.5 4.1 1
12 78 adeno
EGFR mut.
yes oss 60 4.0 4 54 1.5 0.0 2.6 0
13 64 adeno
NSCLC
yes oss, adr,
oth
50 1.4 7 3 0.5 0.0 3.4 2
14 68 adeno
NSCLC
no pul, pleura 60 2.2 3 8 1.0 0.5 2.6 1
15 66 squamous
cell
yes hep, adr,
oss
70 1.5 18 8 0.5 0.5 3.0 3
16 65 adeno
NSCLC
yes pul 70 3.3 4 22 1.0 0.5 4.2 0
17 53 adeno
NSCLC
no hep, adr,
oss
70 3.4 7 2 0.5 1.0 3.8 1
NSCLC non-small cell lung cancer, EGFR epidermal growth factor receptor, hep liver, lym extrathoracic lymph nodes, adr adrenal gland, ski skin, oss bones, oth
other organs, pul lung, KPS Karnofsky performance status, MRI magnetic resonance imaging scans, Mol DS-GPA molecular disease-specific graded prognostic
assessment, OS pred nomogram-predicted median survival in months
ainterval between lung cancer diagnosis and presentation with brain metastasis
bpredicted survival per Barnholtz-Sloan nomogram [14]
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survived for a median of 1.2 months from imaging diag-
nosis of brain metastases.
Results
The first question to the participants from 7 institutions
was whether they would have felt comfortable enrolling
such a patient in the QUARTZ trial. As shown in Table 1,
the likelihood of the seven participants recommending
the QUARTZ trial was low (0–3) for each of the 17 pa-
tients. While one participant would not have recom-
mended the QUARTZ trial to any of the 17 patients,
each of the others would have included at least one of
the 17 patients, while one participant would have recom-
mended the trial to 9 of these patients.
The second question to the participants was regarding
their treatment recommendation (if the QUARTZ trial
would not have been recommended). As shown in
Table 2, these recommendations differed widely for most
of the patients. It was not uncommon to end up with 3
or 4 different suggestions. In general, few participants
(0–2) recommended SC. However, participants acknowl-
edged that patient preferences would be taken into ac-
count. Some kind of local treatment approach was
recommended by the majority of experts for all 17 pa-
tients. Commonly, SRS or SFRT were recommended by
many participants. This was true even for patients with
more than five brain metastases. In the patient with 18
brain metastases, only two participants recommended
WBRT.
The highest agreement among six of seven participants
was for SRS in patient 7 who had one small brain metas-
tasis, lung metastases and an uncontrolled primary
tumor. The second highest agreement among five of
seven participants was for SRS in patient 6 who had one
small brain metastasis, lung metastases and multiple
other extracranial metastases. For patients with multiple
brain metastases of varying size, it was also quite com-
mon that participants suggested a combination of resec-
tion and post-operative SRS/SFRT to the tumor bed and
unresected lesions.
The highest number of participants recommending
WBRT alone (3 of 7 experts) was for patient 11 with five
brain metastases, one in the brainstem, as well as ad-
renal metastases.
The third and final question asked, “If you had a
protocol investigating radiotherapy utilization in the last
30 days of life (assessment of biomarkers, symptoms and
quality-of-life items predicting early death), would you
recommend it for this patient based on the prognostic
information available in the distributed material”? This
question related to the often expressed concern that ra-
diation therapy during the last 30 days of life may be fu-
tile. As shown in Table 3, the highest agreement, in five
of seven participants, was registered in patient 4 who
had a large single brainstem metastasis, uncontrolled
malignant pleural effusion and other extracranial metas-
tases. In eight other cases, a majority of participants (4
of 7) would have included the patient in this hypothet-
ical protocol. The highest agreement against inclusion (0
of 7) was found in patient 16, who actually had died 0.5
months after start of WBRT. Only 1/7 would have in-
cluded patient 6, who actually was managed with SC and
died 2 months after diagnosis of brain metastases. Pa-
tient 11 had the longest survival (5.3 months, treated
with WBRT) and would have been included by 2/7 par-
ticipants. The patient with the second shortest survival
after WBRT (0.6 months, patient 13) would have been
included by 4/7 participants.
Discussion
The QUARTZ trial of WBRT plus SC or SC alone had dif-
ficulties in patient accrual [19]. The present finding of lim-
ited willingness to enroll patients that fulfil the eligibility
criteria suggests that experienced clinicians expect little, if
any, benefit from palliative WBRT with the 4 Gy × 5 regi-
men. In fact, the biologically equivalent dose of this regi-
men is unlikely to provide major tumor shrinkage and
long-lasting growth control [22, 23]. Historically, WBRT
has long been the most widely used treatment for brain
metastases from NSCLC (often 3 Gy × 10), from todays
point of view based on sub-optimal evidence from studies
that are difficult to translate into current practice (pre--
MRI era, limited possibilities to determine the TNM stage
correctly, limited possibilities to treat extracranial disease).
Opponents of WBRT commonly point out its negative im-
pact on health-related quality-of-life (fatigue, physical
functioning, cognitive functioning), even if these effects
are often transitory as published by Soffietti et al. who re-
ported a randomized trial of WBRT versus observation
after surgical resection or SRS [24]. Since a detailed dis-
cussion of detrimental effects from all available publica-
tions is beyond the scope of this study, the readers are
refered to a recent review [25].
The participants often recommended SRS and SFRT
regimens, likely in an attempt to improve symptoms (all
17 patients had symptomatic brain metastases rather than
imaging or screening detected lesions) and to prevent
imminent death from uncontrolled intracranial disease. A
proportion of patients seen for consultation express the
wish to prevent neurological symptoms such as paresis,
blindness or aphasia, even if they realize that life expec-
tance is short. In addition, in today’s day and age, SRS and
SFRT treatment is not particularly time consuming for the
patient and frequently well tolerated. In fact SRS has be-
come more convenient to plan and deliver, with minimal
imposition of time commitment on the part of the patient,
and results in minimal interruption of daily life schedule.
However, a prospective head to head comparison of SRS/
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SFRTand SC, providing firm support for SRS/SFRT in this
setting, is not available. In principle, the competing risk of
death from thoracic disease and/or extracranial metastases
might limit the net benefit of effective local brain-directed
treatment. An over-optimistic estimation of patients’
prognosis may partially explain the utilization of radio-
therapy near the end of life. Recent studies have tried to
quantify utilization rates [16, 26] and have also suggested
prognostic models, which may lead to improved
decision-making by radiation oncologists [11, 14, 17, 27–29].
However, the perfect prognostic model has yet to be
developed.
For the 7 patients managed with WBRT (4 Gy × 5) the
median survival was 1.3 months measured from the first
day of radiotherapy. This means that several patients re-
ceived WBRT during the last 30 days of life. Interest-
ingly, many participating experts were aware of this risk
and were willing to include at least some of the patients
in a hypothetical protocol addressing aspects of radio-
therapy utilization in the terminal phase of disease.
However, agreement between experts was modest and
not necessarily reflective of actual survival. These find-
ings are in agreement with previous research, as
reviewed by Hui [30].
Since the design of the QUARTZ trial, eligibility cri-
teria for resection and SRS have evolved. Current guide-
lines reflect the heterogeneity of the patient population
and this results in a need for shared decision-making
Table 2 Patient characteristics and treatment recommendations if the QUARTZ trial would not have been recommended
Patient
nr.
Age in
years
NSCLC type DS-
GPA
Predicted risk of
early deatha
Predicted probability
of survival > 12 mo
Actual
survival
Treatment
recommended
Evidence for advantage from WBRT
(level 1b) from the QUARTZ trial
based on Forest plot of overall survival
1 69 squamous
cell
0.5 97 0 0.4b SFRT: 4 (SC: 1) Nom
2 60 poorly diff. 1.0 68 10 0.3b SRS: 4 (SC: 1) No
3 58 adeno NSCLC 1.0 Not eligible Not eligible 1.4b SFRT: 3 (SC: 1)c Yes (reason: age < 60)
4 69 poorly diff. 1.0 73 6 1.6b SFRT: 4 (SC: 1) No
5 61 poorly diff. 0.0 82 3 1.0b SFRT: 4 (SC: 1)d No
6 64 squamous
cell
1.5 65 9 2.0b SRS: 5 (SC: 1) No
7 85 squamous
cell
1.0 81 3 0.6b SRS: 6 No
8 66 adeno NSCLC 0.0 41 20 1.8b SRS: 3 (SC: 1)e No
9 65 poorly diff. 0.5 89 3 2.3b SRS: 2 (SC: 1)f No
10 77 adeno NSCLC 1.0 83 4 0.7b SRS: 3 (SC: 1)g No
11 62 adeno NSCLC 0.5 44 18 5.3 SRS: 4 (SC: 1)h No
12 78 adeno EGFR
mut.
0.0 95 0 2.6 SFRT: 2 (SC: 2)i No
13 64 adeno NSCLC 0.0 71 8 0.6 SRS: 3 (SC: 1) No
14 68 adeno NSCLC 0.5 73 6 1.9 SFRT: 3 (SC: 1)j No
15 66 squamous
cell
0.5 66 9 1.2 WBRT: 2 (SC: 2) No
16 65 adeno NSCLC 0.5 84 3 0.5 SFRT: 4 (SC: 1)k No
17 53 adeno NSCLC 1.0 79 4 1.3 Resection: 2
(SC: 2)l
Yes (reason: age < 60)
anomogram predicts early death (< 3months) and survival > 12 months after SRS (Zindler et al. [15])
boptimal supportive care (nr. 11–17: whole-brain radiotherapy with 5 fractions of 4 Gy; survival in months)
ctwo would have combined SFRT and SRS, another two had a strong preference for resection of the largest lesion
dthree would have combined SFRT and SRS
eone would have combined SRS and WBRT, two would have given WBRT alone
ftwo had a strong preference for resection of the largest lesion
gtwo would have given WBRT alone
hone would have combined SRS and WBRT, one would have combined SFRT and SRS, two would have given WBRT alone
itwo had a strong preference for resection of the largest lesion, two would have included WBRT as component of care, one would have combined SFRT and SRS
jtwo had a strong preference for resection of the largest lesion, one would have combined SFRT and SRS
kone had a strong preference for resection of the cerebellar lesion, one would have combined SFRT and SRS, one would have combined SFRT and WBRT
lresection would have followed by SFRT/SRS to other lesions/cavity, one would have combined SFRT and SRS, one would have given WBRT alone
mthe Forest plot showed improved survival 1) for patients aged younger than 60 years and 2) those with GPA 2.5–3.0
NSCLC: non-small cell lung cancer; EGFR: epidermal growth factor receptor; DS-GPA: disease-specific graded prognostic assessment; WBRT: whole-brain
radiotherapy; SFRT: stereotactic fractionated radiotherapy; SRS: stereotactic single-fraction radiosurgery
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Table 3 Patient characteristics and answers to the question about inclusion in a hypothetical study investigating RT utilization in the
last 30 days of life (identification of predictive factors, e.g., blood biomarkers and symptom severity)
Patient
nr.
Age in
years
NSCLC
type
Primary tumor
controlled
Other
metastases
KPS Largest lesion
size [cm]
Lesion number
(MRI)
Time int.
[mo]a
Mol DS-
GPA
DS-
GPA
OS
pred
EoL study
incl.
1 69 squamous cell yes hep 50 3.8 3 10 1.0 0.5 2.3 4
2 60 poorly diff. no lym, adr, hep,
ski
50 1.3 2 2 1.0 1.0 2.7 4
3 58 adeno NSCLC no hep, oss, oth 60 4.5 3 0 1.0 1.0 3.1 4
4 69 poorly diff. no hep, oss 60 2.1 1 8 1.0 1.0 2.6 5
5 61 poorly diff. no hep, adr, pul 60 3.3 7 10 0.5 0.0 2.6 4
6 64 squamous cell no pul, kidney 70 1.5 1 20 1.0 1.5 2,6 1
7 85 squamous cell no pul 60 1.8 1 18 0.5 1.0 <
2.0
2
8 66 adeno NSCLC no oss, adr, lym 60 1.0 7 0 0.5 0.0 2.8 4
9 65 poorly diff. no pul, oth 50 2.0 2 5 1.0 0.5 2.4 4
10 77 adeno NSCLC yes none 50 2.3 6 12 1.0 1.0 3.8 2
11 62 adeno NSCLC yes adr 70 2.1 5 29 0.5 0.5 4.1 2
12 78 adeno EGFR
mut.
yes oss 60 4.0 4 54 1.5 0.0 2.6 3
13 64 adeno NSCLC yes oss, adr, oth 50 1.4 7 3 0.5 0.0 3.4 4
14 68 adeno NSCLC no pul, pleura 60 2.2 3 8 1.0 0.5 2.6 2
15 66 squamous cell yes hep, adr, oss 70 1.5 18 8 0.5 0.5 3.0 4
16 65 adeno NSCLC yes pul 70 3.3 4 22 1.0 0.5 4.2 0
17 53 adeno NSCLC no hep, adr, oss 70 3.4 7 2 0.5 1.0 3.8 3
NSCLC non-small cell lung cancer, EGFR epidermal growth factor receptor, hep liver, lym extrathoracic lymph nodes, adr adrenal gland, ski skin, oss bones, oth
other organs, pul lung, KPS Karnofsky performance status, MRI magnetic resonance imaging scans, Mol DS-GPA molecular disease-specific graded prognostic
assessment, OS pred nomogram-predicted median survival in months, RT radiotherapy, EoL end of life
ainterval between lung cancer diagnosis and presentation with brain metastasis
Table 4 Selected guidelines for treatment of brain metastases
Guideline Ref. Published NSCLC specific Important recommendations and messages
EANO [31] 2017 No, but contains a NSCLC section
with main focus on systemic
therapy
The decision regarding whether to employ SRS, SFRT, WBRT, alone or in
combination, for patients with multiple brain metastases comes down to
clinical discretion, patient preference and logistical considerations with the
absolute number of brain metastases becoming less crucial
WBRT or best supportive care should be considered for patients with short
life expectancy (low KPS score and/or progressive systemic disease)
UK NICE [32] 2018 No Consider maximal local therapy with either surgery, SRS or SFRT for people
with a single brain metastasis
Consider SRS/SFRT for people with multiple brain metastases who have
controlled or controllable extracranial disease and KPS of 70 or more; take
into account the number and total volume of metastases
Do not offer WBRT to people with NSCLC and brain metastases that are not
suitable for surgery or SRS/SFRT and have a KPS of under 70
National
Norwegian
guideline
[33] 2018 Yes SRS/SFRT should be considered for 1–4 brain metastases
If ECOG PS 3–4 SC is recommended, if better PS and > 4 brain metastases
WBRT is recommended (4 Gy × 5 or 3 Gy × 10)
Princess Margaret
Cancer Centre
[34] 2018 No The standard of care for patients with brain metastases is currently in a
state of flux
WBRT is our usual recommendation for patients with > 4–6 brain
metastases
EANO European Association of Neuro-Oncology, NSCLC non-small cell lung cancer, SRS stereotactic radiosurgery, SFRT stereotactic fractionated radiotherapy, WBRT
whole-brain radiotherapy, KPS Karnofsky performance status, UK NICE United Kingdom National Institute for Health and Care Excellence, ECOG Eastern Cooperative
Oncology Group, SC supportive care
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and discussion of patient preferences if several options
are available [31] (Table 4). Also in the present study
recommendations differed widely for most of the pa-
tients. It was not uncommon to end up with 3 or 4 dif-
ferent suggestions, a finding that underlines how
difficult it is to interpret the published studies and to
generate evidence-based recommendations. If seeking
additional advice from other providers, e.g. second opin-
ion, many patients may receive different treatment pro-
posals, and also actual treatment is likely more
stochastic than desirable. In general, few recommenda-
tions (0–2) were given towards SC. It was more com-
mon for patients with multiple metastases of varying
size that experts suggested combinations of resection,
post-operative SRS/SFRT and SRS/SFRT to intact le-
sions. These individualized approaches have the poten-
tial to result in long-term survival even in patients with
Lung-molGPA 0–1 (the group with poorest survival;
four prognostic strata in total), as shown in the dataset
published by Sperduto et al. [12]. Median survival was 5.3
and 6.9months in patients with non-adenocarcinoma and
adenocarcinoma, respectively. An important aspect to
consider is the mix of patients with low- and high-volume
brain metastases. The patients selected for our study were
heavily weighted towards unfavorable size and location of
the lesions. Furthermore, except for patient 12, they
lacked driver mutations for targeted systemic therapy. The
presence of such targets (ROS1, ALK, EGFR etc.) compli-
cates decision-making because the optimal role of radio-
therapy in the multimodal setting is still under debate.
Fortunately, systemic treatment is able to increase
survival in eligible patients, sometimes beyond 5 years
[35]. There is a clear need for additional prospective
studies in this challenging patient population to im-
prove prognostic tools and treatment decisions. An
important, recently launched phase III trial (WBRT
versus SRS for 4–10 brain metastases) unfortunately
has already been closed because of lack of accrual
[36], while a different trial is still open (WBRT versus
SRS for 5–15 brain metastases; NCT03550391). Prob-
ably, inclusion bias is problematic for randomized tri-
als, in particular if one can choose reimbursed
treatments without level I evidence.
Conclusions
The frequency of recommendations for WBRT was
low, despite technologically advanced variants that in-
clude hippocampal sparing or simultaneous integrated
boost. Even in patients with adverse prognostic fea-
tures that raised the experts’ awareness of an in-
creased risk of futile treatment near the end of life,
SRS or SFRT were more often recommended than
SC, unless a patient clearly expressed the desire to
forego active treatment.
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